American Cutaneous Leishmaniasis: A Polymorphic Disease
Abstract
Due to the worldwide importance of this theme, we present a case of American cutaneous leishmaniasis in a 65-year- -old patient with restricted skin involvement, despite its long evolution (> 3 years). It was a difficult case to diagnose due to the atypical clinical presentation (large ulcer) and inconclusive histopathological study in the initial biopsies. The third biopsy with careful observation and the contribution of an immunohistochemical study allowed a correct diagnosis and cure after 30 administrations of N-methylglucamine antimoniate ev.
Downloads
References
Belda Junior W, Di Chiacchio Di N, Criado PR. Tratado de Dermatologia. 2ª ed. São Paulo: Atheneu; 2014.
Ejaz A, Raza N, Iftikhar N. Recurrent cutaneous leishmaniasis presenting as sporotrichoid abscesses: A rare presentation near Afghanistan border. Dermatol Online J. 2007; 13:15.
David Azulay R, Rubem Azulay D, Azulay Abulafia L. Azulay Dermatologia. 6ª ed Rio de Janeiro: Guanabara Koogan; 2015.
Ourives-Neves L, Chrusciak-Talhari A, Gadelha EPN, da Silva Júnior RM, Guerra JA, Ferreira LC, et al. A randomized clinical trial comparing meglumine antimoniate, pentamidina and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis. An
Bras Dermatol. 2011; 86:1092-101.
Brasil, Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância Epidemiológica. Manual de Vigilância da Leishmaniose Tegumentar Americana. 2ª ed. – Brasília: Editora do Ministério da Saúde; 2013.
Couto DV, Hans-Filho G, Medeiros MZ, Vicari CFS, Barbosa AB, Takita LC. Leishmaniose tegumentar americana – um caso de desafio terapêutico. An Bras Dermatol. 2014; 89:978-80.
Araujo LM, Maia DC, Agonio B, Cerdan LM, Galvão RS, Francesconi do Valle VA, et al. Leishmaniose tegumentar americana - apresentação atípica diagnosticada com técnica de biologia molecular. Rev Soc Port Dermatol Venereol. 2015; 73:479-83.
Lima MV, Oliveira RZ, Lima AP, Cerino DA, Silveira TG. American cutaneous leishmaniasis with fatal outcome during pentavalent antimoniate treatment. An Bras Dermatol. 2007; 82:269-71.
Miltropoulos P, Konidas P, Durkin-Konidas M. New World cutaneous leishmaniasis: update review of current and future diagnosis and treatment. J Am Acad Dermatol. 2010; 63:309-22.
Machado-Pinto J, Pinto j, Costa CA, Genaro O, Marques MJ, Modabber F, et al. Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania amazonensis vaccine plus antimonial. Int J Dermatol. 2002; 41:73-8.
Marsden PD, Sampaio RN, Carvalho EM, Veiga JP, Costa JL, Llanos-Cuentas EA. High continuous Antimony therapy in two patients with unresponsive mucosal leishmaniasis. Am J Trop Med Hyg. 1985; 34:710-3.
Mattos MS, Friedman RK, Silva Filho IL, Oliveira-Neto MP. Pancreatite: um dos efeitos adversos da terapia antimonial na leishmaniose. An Bras Dermatol. 1991; 75:45-50.
Mayrink W, Michlick MS, Melo MN, Williams P, Nascimento E, Araújo P, et al. Tratamento da leishmaniose tegumentar Americana utilizando vacina. An Bras Dermatol. 1991; 66:55-9.
González U. Fluconazol for cutaneous leishmaniosis: looking for a better treatment. Arch Dermatol. 2002; 138:1604-6.
Lima MV, Oliveira RZ, Lima AP, Cerino DA, Silveira TG. Leishmaniose cutânea com desfecho fatal durante o tratamento com antimonial pentavalente. An Bras Dermatol. 2007; 82:269-71.
Sadeghian G, Nilforoushzadeh MA. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol. 2006; 45:819-21.
All articles in this journal are Open Access under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
